Belite Bio, Inc (BLTE)
BLTE Stock Price Chart
Explore Belite Bio, Inc interactive price chart. Choose custom timeframes to analyze BLTE price movements and trends.
BLTE Company Profile
Discover essential business fundamentals and corporate details for Belite Bio, Inc (BLTE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Apr 2022
Employees
25.00
Website
https://belitebio.comCEO
Yu-Hsin Lin
Description
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Financial Timeline
Browse a chronological timeline of Belite Bio, Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.73.
Earnings released on 20 May 2026
EPS came in at -$0.34 surpassing the estimated -$0.60 by +43.33%.
Earnings released on 2 Mar 2026
EPS came in at -$0.38 surpassing the estimated -$0.56 by +32.14%.
Earnings released on 10 Nov 2025
EPS came in at -$0.65 falling short of the estimated -$0.53 by -22.64%.
Earnings released on 11 Aug 2025
EPS came in at -$0.50 falling short of the estimated -$0.47 by -6.38%.
Earnings released on 13 May 2025
EPS came in at -$0.45 falling short of the estimated -$0.36 by -25.00%.
Earnings released on 17 Mar 2025
EPS came in at -$0.32 falling short of the estimated -$0.30 by -6.67%.
Earnings released on 12 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%.
Earnings released on 9 Aug 2024
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%.
Earnings released on 13 May 2024
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 11 Mar 2024
EPS came in at -$0.25 surpassing the estimated -$0.36 by +30.56%.
Earnings released on 13 Nov 2023
EPS came in at -$0.40 falling short of the estimated -$0.31 by -29.03%.
Earnings released on 8 Aug 2023
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%.
Earnings released on 10 May 2023
EPS came in at -$0.33 falling short of the estimated -$0.20 by -65.00%.
Earnings released on 31 Mar 2023
EPS came in at -$1.04 falling short of the estimated -$0.22 by -374.41%.
Earnings released on 30 Sept 2022
EPS came in at -$0.10 .
Earnings released on 10 Aug 2022
EPS came in at -$0.12 surpassing the estimated -$0.23 by +49.67%.
Earnings released on 29 Apr 2022
EPS came in at -$0.26 .
Earnings released on 31 Mar 2022
EPS came in at -$0.05 .
Earnings released on 30 Sept 2021
EPS came in at -$0.26 .
BLTE Stock Performance
Access detailed BLTE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
